SCHUCHERT JOSEPH S

Form 4 January 25, 2006

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

if no longer subject to Section 16. Form 4 or Form 5

obligations

Check this box

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

may continue. See Instruction

1(b).

(Last)

(City)

(Print or Type Responses)

1. Name and Address of Reporting Person *

(First)

(State)

KELSO PARTNERS V L P

2. Issuer Name and Ticker or Trading

Symbol

ENDO PHARMACEUTICALS HOLDINGS INC [ENDP]

(Middle) 3. Date of Earliest Transaction

> (Month/Day/Year) 12/29/2005

(Street) 4. If Amendment, Date Original

Filed(Month/Day/Year)

3.

Applicable Line)

Form filed by One Reporting Person _X_ Form filed by More than One Reporting

6. Individual or Joint/Group Filing(Check

5. Relationship of Reporting Person(s) to

(Check all applicable)

10% Owner Other (specify

Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

Issuer

below)

Director

Officer (give title

NEW YORK, NY 10022

320 PARK AVENUE

2. Transaction Date 2A. Deemed 1.Title of Security (Month/Day/Year) Execution Date, if (Instr. 3) (Month/Day/Year)

(Zip)

Code Disposed of (D) (Instr. 8)

TransactionAcquired (A) or (Instr. 3, 4 and 5)

4. Securities

5. Amount of Securities Beneficially Owned Following Reported

Form: Direct (D) or Indirect (I) (Instr. 4)

Indirect Beneficial Ownership (Instr. 4)

6. Ownership 7. Nature of

OMB APPROVAL

3235-0287

January 31,

2005

0.5

OMB

Number:

Expires:

response...

Estimated average

burden hours per

(A) Transaction(s) or (Instr. 3 and 4) Code V Amount (D) Price

Common

Stock, par 12/29/2005 value \$.01 per share (1)

X 2,226

D \$3

15,423,526 I by Endo Pharma

LLC (2) (3)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: SCHUCHERT JOSEPH S - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number on Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Call Obligation (obligation to sell)	\$ 3	12/29/2005		X		2,226	10/13/2005	08/26/2007	Common Stock	2,226

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
KELSO PARTNERS V L P 320 PARK AVENUE NEW YORK, NY 10022		X				
BERNEY PHILIP E C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022		X				
BYNUM FRANK K C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022		X				
GOLDBERG MICHAEL B C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022	X	X				
Loverro Frank J C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022	X	X				
MATELICH GEORGE E C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022		X				
SCHUCHERT JOSEPH S C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022		X				
WAHRHAFTIG DAVID I C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022	X	X				

Reporting Owners 2

WALL THOMAS R IV

C/O KELSO & COMPANY 320 PARK AVENUE X

NEW YORK, NY 10022

Connors James J II

C/O KELSO & COMPANY 320 PARK AVENUE X

NEW YORK, NY 10022

Signatures

/s/James J. Connors, II 01/25/2006

**Signature of Reporting Person Date

James J. Connors, II by Power of

Attorney 11/08/2005

**Signature of Reporting Person Date

James J. Connors, II by Power of 11/09/2005

Attorney 11/09/2005

**Signature of Reporting Person Date

James J. Connors, II by Power of 11/08/2005

Attorney

**Signature of Reporting Person Date

James J. Connors, II by Power of 11/08/2005

Attorney

**Signature of Reporting Person Date

James J. Connors, II by Power of 11/08/2005

Attorney

**Signature of Reporting Person Date

James J. Connors, II by Power of 11/08/2005

Attorney

**Signature of Reporting Person Date

James J. Connors, II by Power of 11/08/2005

Attorney

**Signature of Reporting Person Date

James J. Connors, II by Power of 11/08/2005

Attorney

**Signature of Reporting Person Date

James J. Connors, II by Power of 11/08/2005

Attorney

**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Kelso Partners V, L.P. (KP V") is the designated filer.

(2)

Signatures 3

Edgar Filing: SCHUCHERT JOSEPH S - Form 4

KP V may be deemed to share beneficial ownership of shares of Common Stock owned of record by Endo Pharma LLC by virtue of its status as a member of Endo Pharma LLC. KP V shares investment and voting power along with the other members of Endo Pharma LLC with respect to securities owned by Endo Pharma LLC, but disclaims beneficial ownership of such securities except to the extent of its pecuniary interest.

Each individual reporting person may be deemed to share beneficial ownership of shares of Common Stock owned of record by KP V, by virtue of his status as a general partner of the general partner of KP V, and each individual shares investment and voting power along with the other general partners of KP V, but disclaims beneficial ownership of such securities except to the extent of his pecuriary interest.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.